Cellular Immunotherapy for Acute Myeloblastic Leukemia is under clinical development by MediGene and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Cellular Immunotherapy for Acute Myeloblastic Leukemia’s likelihood of approval (LoA) and phase transition for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) took place on 21 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cellular Immunotherapy for Acute Myeloblastic Leukemia Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Cellular Immunotherapy for Acute Myeloblastic Leukemia overview
Cellular immunotherapy is under development for post-remission therapy in acute myeloid leukemia (AML). The vaccine is administered as an intradermal injection. It uses autologous dendritic cells transfected with RNA encoding two leukemia-associated antigens and one CMV antigen.
MediGene is a biotechnology company which develops innovative immunotherapies to treat cancer with candidates in clinical and pre-clinical development. It focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects and kills tumor cells and T-cell-specific monoclonal antibodies (TAB’s), for isolation of antibodies for monitoring and tracking of TCR-Ts. The company has operational presence in the US and Europe. MediGene is headquartered in Planegg, Germany.
Quick View Cellular Immunotherapy for Acute Myeloblastic Leukemia LOA Data
|Highest Development Stage|